Skip to main content

Table 2 Point prevalencea of the COVID-19 at-risk population in the UK on 5 March 2019, N = 2,706,053

From: UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records

   Scotland Northern Ireland Wales England
N = 801,352 N = 205,092 N = 708,670 N = 990,939
   n Point prevalence /100,000 (95% CI) n Point prevalence /100,000 (95% CI) n Point prevalence /100,000 (95% CI) n Point prevalence /100,000 (95% CI)
Demographics Mean age (SD)   42.3 (22.6)   40.7 (22.7)   42.6 (23.2)   40.8 (22.8)
Female 403,151 50,309 (50,199–50,418) 102,545 50,000 (49,783–50,216) 356,080 50,246 (50,130–50,363) 496,988 50,153 (50,055–50,252)
Ethnicity
 White 427,954 53,404 (53,295–53,513) 55,293 26,960 (26,768–27,153) 226,425 31,951 (31,842–32,059) 570,706 57,592 (57,495–57,690)
 South Asian 9325 1164 (1140–1187) 764 373 (347–400) 7440 1050 (1026–1074) 48,334 4878 (4835–4920)
 Black 3989 498 (482–513) 335 163 (146–182) 2861 404 (389–419) 27,947 2820 (2788–2853)
 Other 9360 1168 (1145–1192) 1102 537 (506–570) 4497 635 (616–653) 20,106 2029 (2001–2057)
 Mixed 2323 290 (278–302) 253 123 (109–140) 2219 313 (300–326) 12,376 1249 (1227–1271)
 Not recorded 348,401 43,477 (43,368–43,585) 147,345 71,843 (71,648–72,038) 465,228 65,648 (65,537–65,759) 311,470 31,432 (31,340–31,523)
Underlying health conditions contributing to the at-risk population Chronic liver disease 4125 515 (499–531) 681 332 (308–358) 2150 303 (291–316) 2525 255 (245–265)
Chronic heart disease 39,804 4967 (4920–5015) 9740 4749 (4657–4842) 34,459 4862 (4813–4913) 37,040 3738 (3701–3775)
Chronic respiratory disease (other than asthma) 28,529 3560 (3520–3601) 7846 3826 (3743–3910) 24,192 3414 (3372–3456) 26,821 2707 (2675–2739)
Current asthma (only) 47,164 5886 (5834–5937) 14,636 7136 (7025–7249) 51,783 7307 (7247–7368) 61,762 6233 (6185–6280)
Chronic neurological disease 29,631 3698 (3656–3739) 6729 3281 (3204–3359) 23,850 3365 (3324–3408) 27,488 2774 (2742–2806)
Diabetes mellitus 54,987 6862 (6807–6917) 15,878 7742 (7627–7858) 59,995 8466 (8401–8531) 61,925 6249 (6202–6297)
Organ transplant recipient 748 93 (87–100) 182 89 (76–103) 653 92 (85–99) 894 90 (84–96)
Asplenia/sickle cell disease 1062 133 (125–141) 244 119 (105–135) 905 128 (120–136) 1337 135 (128–142)
Other immunosuppression 7199 898 (878–919) 1616 788 (750–827) 4181 590 (572–608) 6419 648 (632–664)
Chronic kidney disease 54,845 6844 (6789–6900) 17,296 8433 (8313–8554) 53,280 7518 (7457–7580) 69,894 7053 (7003–7104)
Severe obesity (BMI ≥40 kg/m2) 21,249 3315 (3271–3359) 5256 3299 (3211–3387) 21,431 3803 (3753–3853) 21,282 2762 (2725–2799)
At-risk population based on underlying health conditions At-risk population overallb 196,378 24,506 (24,412–24,600) 53,945 26,303 (26,112–26,494) 187,695 26,486 (26,383–26,588) 223,587 22,563 (22,481–22,646)
 among those aged < 70 years 126,695 /696,563 18,189 (18,098–18,279) 36,178 /180,643 20,027 (19,843–20,213) 117,628 /603,155 19,502 (19,402–19,602) 143,305 /866,280 16,543 (16,464–16,621)
 among those aged ≥70 years 69,683 /104,789 66,498 (66,212–66,784) 17,767 /24,449 72,670 (72,106–73,228) 70,067 /105,515 66,405 (66,119–66,690) 80,282 /124,659 64,401 (64,135–64,667)
 of school age (5–18 years) 9680 /127,199 7610 (7465–7757) 3737 /35,846 10,425 (10,111–10,746) 10,105 /115,258 8767 (8605–8932) 13,915 /175,447 7931 (7805–8059)
 of working age (19–65 years) 99,786 /508,725 19,615 (19,506–19,724) 27,944 /129,274 21,616 (21,392–21,842) 91,644 /433,284 21,151 (21,030–21,273) 111,409 /618,404 18,016 (17,920–18,112)
 among males 93,319 /398,201 23,435 (23,304–23,567) 25,691 /102,534 25,056 (24,791–25,323) 89,178 /352,556 25,295 (25,151–25,439) 106,989 /493,908 21,662 (21,547–21,777)
 among females 103,059 /403,151 25,563 (25,429–25,698) 28,251 /102,545 27,550 (27,277–27,824) 98,513 /356,080 27,666 (27,519–27,813) 116,594 /496,988 23,460 (23,342–23,578)
Multimorbidity 58,076 7247 (7191–7304) 16,248 7922 (7806–8040) 55,556 7839 (7777–7902) 60,994 6155 (6108–6203)
Cancer survivors Incident cancer in previous year 3439 429 (415–444) 899 438 (410–468) 3164 446 (431–462) 3742 376 (364–388)
Incident cancer in previous 5 years 12,847 1603 (1576–1631) 3344 1630 (1576–1686) 12,451 1757 (1726–1788) 14,663 1480 (1456–1504)
  1. SD standard deviation, 95% CI 95% confidence interval, BMI body mass index
  2. aPoint prevalence estimates using standalone primary care records
  3. bThe at-risk population comprised individuals with: any history of chronic respiratory disease other than asthma, heart disease, kidney disease, neurological conditions such as multiple sclerosis, diabetes mellitus; or with current asthma, severe obesity, or immunosuppression; assessed at each index date.